BACKGROUND: The RUNX1 (AML1) gene is a frequent mutational target in myelodysplastic syndromes and acute myeloid leukemia. Previous studies suggested that RUNX1 mutations may have pathological and prognostic implications. DESIGN AND METHODS: We screened 93 patients with cytogenetically normal acute myeloid leukemia for RUNX1 mutations by capillary sequencing of genomic DNA. Mutation status was then correlated with clinical data and gene expression profiles. RESULTS: We found that 15 out of 93 (16.1%) patients with cytogenetically normal acute myeloid leukemia had RUNX1 mutations. Seventy-three patients were enrolled in the AMLCG-99 trial and carried ten RUNX1 mutations (13.7%). Among these 73 patients RUNX1 mutations were significantly associated with older age, male sex, absence of NPM1 mutations and presence of MLL-partial tandem duplications. Moreover, RUNX1-mutated patients had a lower complete remission rate (30% versus 73% P=0.01), lower relapse-free survival rate (3-year relapse-free survival 0% versus 30.4%; P=0.002) and lower overall survival rate (3-year overall survival 0% versus 34.4%; P<0.001) than patients with wild-type RUNX1. RUNX1 mutations remained associated with shorter overall survival in a multivariate model including age and the European Leukemia Net acute myeloid leukemia genetic classification as covariates. Patients with RUNX1 mutations showed a unique gene expression pattern with differential expression of 85 genes. The most prominently up-regulated genes in patients with RUNX1-mutated cytogenetically normal acute myeloid leukemia include lymphoid regulators such as HOP homeobox (HOPX), deoxynucleotidyltransferase (DNTT, terminal) and B-cell linker (BLNK), indicating lineage infidelity. CONCLUSIONS: Our findings firmly establish that RUNX1 mutations are a marker of poor prognosis and provide insights into the pathogenesis of RUNX1 mutation-positive acute myeloid leukemia.
BACKGROUND: The RUNX1 (AML1) gene is a frequent mutational target in myelodysplastic syndromes and acute myeloid leukemia. Previous studies suggested that RUNX1 mutations may have pathological and prognostic implications. DESIGN AND METHODS: We screened 93 patients with cytogenetically normal acute myeloid leukemia for RUNX1 mutations by capillary sequencing of genomic DNA. Mutation status was then correlated with clinical data and gene expression profiles. RESULTS: We found that 15 out of 93 (16.1%) patients with cytogenetically normal acute myeloid leukemia had RUNX1 mutations. Seventy-three patients were enrolled in the AMLCG-99 trial and carried ten RUNX1 mutations (13.7%). Among these 73 patientsRUNX1 mutations were significantly associated with older age, male sex, absence of NPM1 mutations and presence of MLL-partial tandem duplications. Moreover, RUNX1-mutated patients had a lower complete remission rate (30% versus 73% P=0.01), lower relapse-free survival rate (3-year relapse-free survival 0% versus 30.4%; P=0.002) and lower overall survival rate (3-year overall survival 0% versus 34.4%; P<0.001) than patients with wild-type RUNX1. RUNX1 mutations remained associated with shorter overall survival in a multivariate model including age and the European Leukemia Net acute myeloid leukemia genetic classification as covariates. Patients with RUNX1 mutations showed a unique gene expression pattern with differential expression of 85 genes. The most prominently up-regulated genes in patients with RUNX1-mutated cytogenetically normal acute myeloid leukemia include lymphoid regulators such as HOP homeobox (HOPX), deoxynucleotidyltransferase (DNTT, terminal) and B-cell linker (BLNK), indicating lineage infidelity. CONCLUSIONS: Our findings firmly establish that RUNX1 mutations are a marker of poor prognosis and provide insights into the pathogenesis of RUNX1 mutation-positive acute myeloid leukemia.
Authors: Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert L Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joelle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria-Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann Journal: J Clin Oncol Date: 2006-06-01 Impact factor: 44.544
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: A Venditti; G Del Poeta; F Buccisano; A Tamburini; M C Cox-Froncillo; G Aronica; A Bruno; B Del Moro; A M Epiceno; A Battaglia; L Forte; M Postorino; V Cordero; S Santinelli; S Amadori Journal: Leukemia Date: 1998-07 Impact factor: 11.528
Authors: Verena I Gaidzik; Lars Bullinger; Richard F Schlenk; Andreas S Zimmermann; Jürgen Röck; Peter Paschka; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Daniela Späth; Andrea Kündgen; Ingo G H Schmidt-Wolf; Katharina Götze; David Nachbaur; Michael Pfreundschuh; Heinz A Horst; Hartmut Döhner; Konstanze Döhner Journal: J Clin Oncol Date: 2011-02-22 Impact factor: 50.717
Authors: Deli Hong; Andrew J Fritz; Jonathan A Gordon; Coralee E Tye; Joseph R Boyd; Kirsten M Tracy; Seth E Frietze; Frances E Carr; Jeffrey A Nickerson; Andre J Van Wijnen; Anthony N Imbalzano; Sayyed K Zaidi; Jane B Lian; Janet L Stein; Gary S Stein Journal: J Cell Physiol Date: 2018-12-04 Impact factor: 6.384
Authors: Jason H Mendler; Kati Maharry; Heiko Becker; Ann-Kathrin Eisfeld; Leigha Senter; Krzysztof Mrózek; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jihane Khalife; Michael A Caligiuri; Rebecca B Klisovic; Joseph O Moore; Thomas H Carter; Guido Marcucci; Clara D Bloomfield Journal: Haematologica Date: 2013-06-10 Impact factor: 9.941
Authors: P Silva; M Neumann; M P Schroeder; S Vosberg; C Schlee; K Isaakidis; J Ortiz-Tanchez; L R Fransecky; T Hartung; S Türkmen; A Graf; S Krebs; H Blum; C Müller-Tidow; C Thiede; G Ehninger; H Serve; J Hecht; W E Berdel; P A Greif; C Röllig; C D Baldus Journal: Leukemia Date: 2017-04-03 Impact factor: 11.528
Authors: Florentien E M In 't Hout; Mylène Gerritsen; Lars Bullinger; Bert A van der Reijden; Gerwin Huls; Edo Vellenga; Joop H Jansen Journal: Haematologica Date: 2019-12-19 Impact factor: 9.941
Authors: Ansuman T Satpathy; Carlos G Briseño; Xiongwei Cai; Drew G Michael; Chun Chou; Sunnie Hsiung; Deepta Bhattacharya; Nancy A Speck; Takeshi Egawa Journal: Blood Date: 2014-03-27 Impact factor: 22.113
Authors: Jesse J C Cheah; Christopher N Hahn; Devendra K Hiwase; Hamish S Scott; Anna L Brown Journal: Int J Hematol Date: 2017-05-25 Impact factor: 2.490
Authors: V I Gaidzik; V Teleanu; E Papaemmanuil; D Weber; P Paschka; J Hahn; T Wallrabenstein; B Kolbinger; C H Köhne; H A Horst; P Brossart; G Held; A Kündgen; M Ringhoffer; K Götze; M Rummel; M Gerstung; P Campbell; J M Kraus; H A Kestler; F Thol; M Heuser; B Schlegelberger; A Ganser; L Bullinger; R F Schlenk; K Döhner; H Döhner Journal: Leukemia Date: 2016-05-03 Impact factor: 11.528
Authors: Beverly W Baron; John Anastasi; Juraj Bies; Poluru L Reddy; Loren Joseph; Michael J Thirman; Kristen Wroblewski; Linda Wolff; Joseph M Baron Journal: Blood Cells Mol Dis Date: 2013-07-30 Impact factor: 3.039